MYO - Myomo, Inc.
| Previous Close | 0.7814 |
| Open | 0.7510 |
| Bid | 0.7600 x 900 |
| Ask | 0.7710 x 1300 |
| Day's Range | 0.7523 - 0.7600 |
| 52 Week Range | 0.6120 - 2.6900 |
| Volume | 2,897 |
| Avg. Volume | 264,042 |
| Market Cap | 13.369M |
| Beta (3Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7380 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Zacks
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
- Zacks
Innovation Aids Genomic Health, Merger Procedure on Track
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
- Zacks
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
Insulet (PODD) has various favorable factors to maintain the current high.
- Simply Wall St.
Before You Buy Myomo, Inc. (NYSEMKT:MYO), Consider Its Volatility
If you own shares in Myomo, Inc. (NYSEMKT:MYO) then it's worth thinking about how it contributes to the volatility of...
- Business Wire
Myomo Announces Technology Licensing Program for International Markets
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. The company will pursue technology licensing arrangements with international partners that can manufacture and distribute the MyoPro products to rehabilitation hospitals and patients in their home markets.
- Business Wire
Myomo Reports Second Quarter 2019 Results
Record Quarterly Revenues and 28% Sequential Expansion of Reimbursement Pipeline
- Business Wire
Myomo to Report Second Quarter 2019 Results on August 8, 2019
August 1, 2019 – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the second quarter ended June 30, 2019 on Thursday, August 8, 2019, after the US markets close. The Company will host a conference call on Thursday, August 8, 2019 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer.
- Zacks
Will Myomo, Inc. (MYO) Report Negative Q2 Earnings? What You Should Know
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
If You Had Bought Myomo (NYSEMKT:MYO) Stock A Year Ago, You'd Be Sitting On A 73% Loss, Today
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
- Business Wire
Myomo Announces First Insurance Reimbursements in European Markets
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced today that its Orthotics and Prosthetics (O&P) distribution partners in Germany and Denmark have successfully obtained their first reimbursement decisions by insurance payers for the MyoPro orthosis. In addition, these O&P providers, along with other certified firms in the UK and Italy, have a growing number of MyoPro units in the reimbursement process.
- Simply Wall St.
What Percentage Of Myomo, Inc. (NYSEMKT:MYO) Shares Do Insiders Own?
The big shareholder groups in Myomo, Inc. (NYSEMKT:MYO) have power over the company. Large companies usually have...
- Business Wire
Myomo® Announces Participation in Beijing Trade Show
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces its participation in the China International Fair for Trade in Services, to be held in Beijing from May 28-31, 2019. Myomo will participate in this event together with Beijing Ryzur Medical Investment Co., Ltd. (Ryzur Medical), a growing medical device manufacturer based in Beijing.
- Zacks
Myomo, Inc. (MYO) Reports Q1 Loss, Lags Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Myomo Reports First Quarter 2019 Results
Reports 165% Year-over-Year Revenue Growth and Continued Expansion of Reimbursement Pipeline
- Business Wire
Myomo to Report First Quarter 2019 Results on May 13, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the first quarter ended March 31, 2019 on Monday, May 13, 2019, before the US markets open. The Company will host a conference call on Monday, May 13, 2019 at 8:30 a.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer.
- Zacks
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Myomo® Announces New Distribution Agreement for Australia / New Zealand
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand. The company achieves this through direct clinical service provision to its own clients in Melbourne and Sydney, and through its sister clinic Interface Orthotics in Perth. In addition, NeuroMuscular Orthotics expands its reach throughout Australia and New Zealand by offering distribution, central fabrication and education to certified orthotist/prosthetists.
- Business Wire
Myomo® Announces New Sales and Service Agreement for Chile
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with Tecnoplanta Orthopedic Laboratory with the goal of offering MyoPro in Chile.
- Business Wire
Myomo® Announces New Sales and Service Agreement for Italy
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with Progettiamo Autonomia Robotics (PAR) with the goal of offering MyoPro in Italy. PAR is a unit of Progettiamo Autonomia, headquartered in Reggio Emilia, Italy, with 17 offices nationwide.
- Business Wire
Myomo Makes NYSE American Section 610(b) Public Announcement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 12, 2019 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2018 included in the 10-K contained an audit opinion from its independent registered public accounting firm, which included a going concern emphasis of matter paragraph. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph.
- Simply Wall St.
What Should Investors Know About Myomo, Inc.’s (NYSEMKT:MYO) Future?
The latest earnings announcement Myomo, Inc. (NYSEMKT:MYO) released in December 2018 revealed that losses became smaller relative to the prior year's level - great news for investors Below is myRead More...
- Business Wire
Myomo Announces Participation at Two Upcoming Investor Conferences
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer David Henry will be presenting, as well as meeting with investors, at two upcoming investor conferences.
- Business Wire
Myomo Reports Fourth Quarter and Year End 2018 Results
Reports Record Revenues and Reimbursement Pipeline for the Fourth Quarter and Full Year
